Sugi Predict

Sugi Predict / Compounds / SCHEMBL5701008

SCHEMBL5701008

SCHEMBL5701008

CC(C)(C)OC(=O)CN1CCC(C(=O)O)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.46
▸ LMNA P02545 1/20 0.42
▸ WNT1 P04628 1/20 0.42
▸ GSK3B P49841 1/20 0.42
▸ DYRK1A Q13627 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HPGD P15428 1/20 0.39
▸ BTK Q06187 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ KMT2A Q03164 1/20 0.38
▸ HTR4 Q13639 1/20 0.38
▸ PLA2G10 O15496 1/20 0.37
▸ PLA2G5 P39877 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ S1PR5 Q9H228 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092415 0.90 HSD17B10 (0.41) HSD17B10LMNAWNT1GSK3BDYRK1A
SCHEMBL2468843 0.90 HSD17B10 (0.41) HSD17B10LMNAWNT1GSK3BDYRK1A
SCHEMBL30886190 0.88 PKM (0.47) HSD17B10LMNASMN1; SMN2HPGDKMT2A
SCHEMBL26891587 0.87 WNT1 (0.42) HSD17B10WNT1GSK3BDYRK1ASMN1; SMN2
SCHEMBL8486056 0.85 SMN1; SMN2 (0.54) WNT1GSK3BDYRK1ASMN1; SMN2KDM4E
SCHEMBL6986660 0.84 SMN1; SMN2 (0.51) HSD17B10LMNASMN1; SMN2HPGDBTK
SCHEMBL7377754 0.84 WNT1 (0.41) HSD17B10WNT1GSK3BDYRK1ASMN1; SMN2
SCHEMBL8140909 0.84 ALDH1A1 (0.49) LMNAWNT1GSK3BDYRK1ASMN1; SMN2
SCHEMBL572705 0.83 CHRM2 (0.41) WNT1GSK3BDYRK1AHPGDKDM4E
SCHEMBL13698802 0.83 SMN1; SMN2 (0.41) WNT1GSK3BDYRK1ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159727-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2026-04-08 — — EP disclosed
US-12415796-B2 Inhibitors of (αv)(β6) integrin MORPHIC THERAPEUTIC, INC. (US) 2025-09-16 — — US disclosed
US-20240327378-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2024-10-03 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-11-28 — — US disclosed
WO-2023161316-A1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-31 — — WO disclosed
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2023-08-17 — — US disclosed
CN-116283977-A Inhibitors of αvβ6 integrin 莫菲克医疗股份有限公司 2023-06-23 — — CN disclosed
CN-110573499-B Inhibitors of αvβ6 integrin 莫菲克医疗股份有限公司 2023-04-21 — — CN disclosed
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-05-21 — — US disclosed
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-05-21 — — US disclosed
US-20200087299-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2020-03-19 — — US disclosed
CN-110573499-A inhibitors of α v β 6 integrin 莫菲克医疗股份有限公司 2019-12-13 — — CN disclosed
WO-2018160521-A2 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Lazuli, Inc. (US) 2018-09-07 — — WO disclosed
US-20180244648-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2018-08-30 — — US disclosed
EP-2731942-B1 NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS NOVARTIS AG (CH) 2015-09-23 — — EP disclosed
EP-1027328-B1 SUBSTITUTED ANILIDES AVENTIS PHARMA LTD (GB) 2006-08-23 — — EP disclosed
US-6479519-B1 INHIBITORS OF CELL ADHESION; TREATMENT OF ASTHMA OR INFLAMMATORY BOWEL DISEASE AVENTIS PHARMA LIMITED (GB) 2002-11-12 — — US disclosed
US-6069143-A Fibrinogen receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2000-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327378-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV HSD17B10 4326/4885LMNA 2000/4885WNT1 1692/4885
US-12415796-B2 Inhibitors of (αv)(β6) integrin ITGB6, ITGA6, ITGAV HSD17B10 4367/4885LMNA 2741/4885WNT1 1751/4885
US-20200087299-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGAV, ITGA6 HSD17B10 4753/4885LMNA 2840/4885WNT1 1588/4885
US-11827621-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV HSD17B10 4410/4885LMNA 2270/4885WNT1 1884/4885
US-20200157075-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV HSD17B10 4326/4885LMNA 2000/4885WNT1 1692/4885
US-20230257343-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP HSD17B10 3966/4885LMNA 3240/4885WNT1 4637/4885
US-20180244648-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV HSD17B10 4326/4885LMNA 2000/4885WNT1 1692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.